Nutriband Strengthens Intellectual Property for Abuse-Deterrent Drug Delivery Technology
Nutriband secures new U.S. trademark and international patents for its AVERSA™ transdermal drug delivery platform, positioning the company to target a significant market opportunity in abuse-deterrent pharmaceuticals.
Nutriband Inc. has expanded its intellectual property protection for its innovative abuse-deterrent drug delivery technology, receiving a new U.S. trademark and an additional international patent that reinforces the company's market strategy.
The pharmaceutical technology company secured a trademark registration from the U.S. Patent and Trademark Office for the Nutriband™ brand, covering pharmaceutical and product research and development. Simultaneously, the company obtained a patent in Macao for its proprietary AVERSA™ transdermal system, bringing its total international patent protection to 46 countries.
The AVERSA™ platform is designed to mitigate risks associated with potent drugs like fentanyl, focusing on reducing potential abuse, unauthorized diversion, and accidental exposure. By developing an advanced abuse-deterrent delivery mechanism, Nutriband is addressing critical challenges in pharmaceutical safety and patient care.
With the fentanyl patch market representing a potential $80 million to $200 million sales opportunity in the United States, Nutriband's strategic intellectual property approach positions the company to compete effectively in this critical healthcare segment. The company has also enhanced its brand visibility through a strategic partnership with Charlotte FC, further supporting its market expansion efforts.
These intellectual property developments underscore Nutriband's commitment to developing innovative pharmaceutical technologies that prioritize patient safety and controlled substance management. By continuously strengthening its patent portfolio, the company is building a robust protective barrier around its technological innovations.